Cinclus Pharma Holding (J8P) Stock Overview
A clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
J8P Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Cinclus Pharma Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.01 |
| 52 Week High | SEK 1.79 |
| 52 Week Low | SEK 0.95 |
| Beta | -0.073 |
| 1 Month Change | -6.48% |
| 3 Month Change | -31.48% |
| 1 Year Change | -27.34% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -64.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| J8P | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 2.4% | -2.5% | -1.2% |
| 1Y | -27.3% | 44.6% | 0.5% |
Return vs Industry: J8P underperformed the German Pharmaceuticals industry which returned 45.7% over the past year.
Return vs Market: J8P underperformed the German Market which returned 0.3% over the past year.
Price Volatility
| J8P volatility | |
|---|---|
| J8P Average Weekly Movement | 8.3% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: J8P's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: J8P's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 17 | Christer Ahlberg | cincluspharma.com |
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company’s lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori.
Cinclus Pharma Holding AB (publ) Fundamentals Summary
| J8P fundamental statistics | |
|---|---|
| Market cap | €50.09m |
| Earnings (TTM) | -€21.66m |
| Revenue (TTM) | €6.12m |
Is J8P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| J8P income statement (TTM) | |
|---|---|
| Revenue | SEK 67.51m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 67.51m |
| Other Expenses | SEK 306.57m |
| Earnings | -SEK 239.07m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 19, 2026
| Earnings per share (EPS) | -5.14 |
| Gross Margin | 100.00% |
| Net Profit Margin | -354.14% |
| Debt/Equity Ratio | 16.3% |
How did J8P perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/14 01:12 |
| End of Day Share Price | 2026/07/14 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cinclus Pharma Holding AB (publ) is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ulrik Trattner | DNB Carnegie |
| Fredrik Thor | Redeye |
| Kevin Sule | Redeye |